OPK

In the past six months, OPKO Health's stock (OPK) has declined, hitting a new 1-year low in late April 2026, with a 52-week range between $0.98 and $1.60. Key events include Q1 2026 financial results reporting a net loss of $54.8 million, or $0.07 per share, with revenues of $124.2 million, missing consensus estimates due to the sale of certain BioReference assets in 2025. Q2 2026 and full-year revenue guidance were below Street estimates. The sale of BioReference Health assets to Labcorp for $237.5 million in 2024-2025 has refocused capital towards pharmaceuticals and royalty streams. As of March 31, 2026, approximately $92.0 million of OPKO's common stock had been repurchased, with about $108.0 million remaining available. Several research firms have reissued "market perform" or "sell" ratings on OPKO Health shares in early 2026, with an average rating of "Hold" and a consensus price target of $1.55.